PH12021550176A1 - Method for treating epilepsy - Google Patents
Method for treating epilepsyInfo
- Publication number
- PH12021550176A1 PH12021550176A1 PH12021550176A PH12021550176A PH12021550176A1 PH 12021550176 A1 PH12021550176 A1 PH 12021550176A1 PH 12021550176 A PH12021550176 A PH 12021550176A PH 12021550176 A PH12021550176 A PH 12021550176A PH 12021550176 A1 PH12021550176 A1 PH 12021550176A1
- Authority
- PH
- Philippines
- Prior art keywords
- fenfluramine
- epileptic seizure
- racemate
- preferred embodiments
- embodiments contemplate
- Prior art date
Links
- 206010015037 epilepsy Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical class CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 abstract 3
- 206010010904 Convulsion Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000028329 epileptic seizure Diseases 0.000 abstract 3
- 201000007547 Dravet syndrome Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 abstract 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 abstract 1
- 230000000573 anti-seizure effect Effects 0.000 abstract 1
- 231100000457 cardiotoxic Toxicity 0.000 abstract 1
- 230000001451 cardiotoxic effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/14—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by a carboxylic acid having the esterifying carboxyl group bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711051P | 2018-07-27 | 2018-07-27 | |
| PCT/US2019/043765 WO2020023923A1 (en) | 2018-07-27 | 2019-07-26 | Method for treating epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12021550176A1 true PH12021550176A1 (en) | 2021-10-11 |
Family
ID=67551433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12021550176A PH12021550176A1 (en) | 2018-07-27 | 2021-01-22 | Method for treating epilepsy |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20200030260A1 (enExample) |
| EP (1) | EP3829558B1 (enExample) |
| JP (1) | JP2021530541A (enExample) |
| KR (1) | KR20210061332A (enExample) |
| CN (1) | CN112930175A (enExample) |
| AU (1) | AU2019310600A1 (enExample) |
| BR (1) | BR112021001135A2 (enExample) |
| CA (1) | CA3106031A1 (enExample) |
| CL (1) | CL2021000196A1 (enExample) |
| CO (1) | CO2021002087A2 (enExample) |
| CR (1) | CR20210095A (enExample) |
| EA (1) | EA202190369A1 (enExample) |
| ES (1) | ES2988130T3 (enExample) |
| IL (1) | IL280128A (enExample) |
| MA (1) | MA53329A (enExample) |
| MX (1) | MX2021000987A (enExample) |
| PE (1) | PE20211065A1 (enExample) |
| PH (1) | PH12021550176A1 (enExample) |
| SG (1) | SG11202100682YA (enExample) |
| WO (1) | WO2020023923A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| SG11201804811WA (en) | 2015-12-22 | 2018-07-30 | Zogenix International Ltd | Fenfluramine compositions and methods of preparing the same |
| KR20180095674A (ko) | 2015-12-22 | 2018-08-27 | 조게닉스 인터내셔널 리미티드 | 대사 저항성 펜플루라민 유사체 및 그 사용 방법 |
| RU2746000C2 (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| WO2020047312A1 (en) * | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
| US12144787B2 (en) | 2018-11-19 | 2024-11-19 | Zogenix International Limited | Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5) |
| CN114127150A (zh) * | 2019-07-18 | 2022-03-01 | 巴斯夫欧洲公司 | 脲基甲酸酯基分散剂 |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| US20230078820A1 (en) * | 2021-09-01 | 2023-03-16 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
| CN118873517A (zh) * | 2024-07-05 | 2024-11-01 | 上海柯西医药科技发展有限公司 | 大麻二酚与5-ht2b受体激动剂的组合的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL270984A (enExample) | 1960-11-05 | |||
| GB1175516A (en) | 1966-04-15 | 1969-12-23 | Science Union & Cie | New Phenyl-Aminopropane Derivatives and Preparations Containing them |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| WO1995033455A1 (en) * | 1994-06-03 | 1995-12-14 | Elmaleh David R | Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof |
| JP2001524124A (ja) | 1997-05-07 | 2001-11-27 | ガレン（ケミカルズ）リミティド | テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具 |
| US6591909B1 (en) | 2001-12-20 | 2003-07-15 | Halliburton Energy Services, Inc. | Whey protein retarder |
| US9549909B2 (en) * | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| CA3204599A1 (en) * | 2015-02-25 | 2016-09-01 | The Regents Of The University Of California | 5ht agonists for treating disorders |
| JP6668045B2 (ja) * | 2015-05-15 | 2020-03-18 | ゾゲニクス インターナショナル リミテッド | ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト |
| JP2017057188A (ja) * | 2015-09-14 | 2017-03-23 | ゾゲニクス インターナショナル リミテッド | 特別な形態のてんかんの併用療法 |
| GB201715919D0 (en) * | 2017-09-29 | 2017-11-15 | Gw Res Ltd | use of cannabinoids in the treatment of epilepsy |
-
2019
- 2019-07-26 MX MX2021000987A patent/MX2021000987A/es unknown
- 2019-07-26 KR KR1020217004603A patent/KR20210061332A/ko not_active Ceased
- 2019-07-26 CR CR20210095A patent/CR20210095A/es unknown
- 2019-07-26 US US16/523,568 patent/US20200030260A1/en active Pending
- 2019-07-26 CN CN201980049623.9A patent/CN112930175A/zh active Pending
- 2019-07-26 CA CA3106031A patent/CA3106031A1/en active Pending
- 2019-07-26 MA MA053329A patent/MA53329A/fr unknown
- 2019-07-26 JP JP2021503108A patent/JP2021530541A/ja active Pending
- 2019-07-26 BR BR112021001135-8A patent/BR112021001135A2/pt not_active IP Right Cessation
- 2019-07-26 ES ES19750214T patent/ES2988130T3/es active Active
- 2019-07-26 EA EA202190369A patent/EA202190369A1/ru unknown
- 2019-07-26 PE PE2021000089A patent/PE20211065A1/es unknown
- 2019-07-26 EP EP19750214.9A patent/EP3829558B1/en active Active
- 2019-07-26 AU AU2019310600A patent/AU2019310600A1/en not_active Abandoned
- 2019-07-26 SG SG11202100682YA patent/SG11202100682YA/en unknown
- 2019-07-26 WO PCT/US2019/043765 patent/WO2020023923A1/en not_active Ceased
-
2021
- 2021-01-12 IL IL280128A patent/IL280128A/en unknown
- 2021-01-22 PH PH12021550176A patent/PH12021550176A1/en unknown
- 2021-01-25 CL CL2021000196A patent/CL2021000196A1/es unknown
- 2021-02-23 CO CONC2021/0002087A patent/CO2021002087A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020023923A1 (en) | 2020-01-30 |
| CA3106031A1 (en) | 2020-01-30 |
| EA202190369A1 (ru) | 2021-06-10 |
| AU2019310600A1 (en) | 2021-02-11 |
| EP3829558C0 (en) | 2024-07-03 |
| MX2021000987A (es) | 2021-06-15 |
| CL2021000196A1 (es) | 2021-12-31 |
| CO2021002087A2 (es) | 2021-04-30 |
| CR20210095A (es) | 2021-06-01 |
| EP3829558B1 (en) | 2024-07-03 |
| ES2988130T3 (es) | 2024-11-19 |
| SG11202100682YA (en) | 2021-02-25 |
| JP2021530541A (ja) | 2021-11-11 |
| KR20210061332A (ko) | 2021-05-27 |
| IL280128A (en) | 2021-03-01 |
| MA53329A (fr) | 2022-03-02 |
| PE20211065A1 (es) | 2021-06-09 |
| EP3829558A1 (en) | 2021-06-09 |
| BR112021001135A2 (pt) | 2021-04-20 |
| CN112930175A (zh) | 2021-06-08 |
| US20200030260A1 (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550176A1 (en) | Method for treating epilepsy | |
| WO2021026218A3 (en) | Treatment of central nervous system disorders | |
| JOP20220061A1 (ar) | علاج الضعف السلوكي في الاعتلال الدماغي النموي والصرعي | |
| PH12019500177A1 (en) | Treatment and prevention of sleep disorders | |
| WO2020086726A3 (en) | Nerve stimulation for treating migraine and other headache conditions | |
| WO2018209022A3 (en) | Methods of treating neuropsychiatric disorders | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| MX389927B (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| MX2010003548A (es) | Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida. | |
| CL2017002242A1 (es) | Método para tratar un tumor cerebral | |
| WO2013059791A3 (en) | Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders | |
| MX2023009631A (es) | Metodos de tratamiento de transtornos convulsivos y sindrome de prader-willi. | |
| MX2017013852A (es) | Produccion escalable de vesiculas extracelulares estandarizadas, preparaciones de vesiculas extracelular y usos de estos. | |
| MX2022009384A (es) | Usos terapeuticos de la tirzepatida. | |
| AU2017261286A1 (en) | Treatment of hair loss disorders with deuterated JAK inhibitors | |
| WO2019236750A3 (en) | Targeted treatment of autism spectrum disorder and other neurological or psychiatric disorders | |
| WO2016127059A3 (en) | Light inhibitors for scleroderma and skin fibrotic disease treatment | |
| IN2013DN11328A (enExample) | ||
| MX2024001269A (es) | Inhibidores de rock2 y sus usos. | |
| MX2023009600A (es) | Análogos de la oxa-ibogaína para el tratamiento de trastornos por consumo de sustancias. | |
| MX2024000701A (es) | Metodos de tratamiento de la enfermedad de alzheimer. | |
| EA202092472A1 (ru) | Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности | |
| MX2022014912A (es) | Tratamiento del trastorno del espectro autista con cannabidiol. | |
| WO2023183613A3 (en) | Indolizine compounds for the treatment of mental disorders or inflammation |